Petros Pharmaceuticals (PTPI) Institutional Ownership $0.03 +0.00 (+0.29%) As of 07/3/2025 12:13 PM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Petros Pharmaceuticals (NASDAQ:PTPI)CurrentInstitutional OwnershipPercentage12.34%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$973.61KNumber ofInstitutional Sellers(last 12 months)0 Get PTPI Insider Trade Alerts Want to know when executives and insiders are buying or selling Petros Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data PTPI Institutional Buying and Selling by Quarter Petros Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2025Jane Street Group LLC563,594$39K0.0%N/A26.324% 8/2/2023Bank of Montreal Can10,000$27K0.0%N/A0.478% 1/27/2022Emfo LLC10,000$33K0.0%-64.3%0.048% 11/12/2021NorthRock Partners LLC115,295$431K0.0%-47.4%1.173% 9/17/2021Virtu Financial LLC14,364$45K0.0%N/A0.146% 8/16/2021Shay Capital LLC238,764$747K0.1%-7.0%2.437% 8/13/2021Renaissance Technologies LLC54,887$172K0.0%-70.4%0.560% 8/13/2021Geode Capital Management LLC23,725$74K0.0%+67.3%0.242% 8/13/2021Vanguard Group Inc.107,500$336K0.0%+21.2%1.097% 8/12/2021NorthRock Partners LLC219,188$686K0.1%-35.1%2.237% 8/10/2021CM Management LLC100,000$313K0.2%+122.2%1.021% 8/5/2021Platform Technology Partners44,000$138K0.1%N/A0.449% 5/21/2021Citadel Advisors LLC35,492$131K0.0%N/A0.362% 5/18/2021Citadel Advisors LLC35,492$131K0.0%N/A0.363% 5/13/2021Renaissance Technologies LLC185,545$692K0.0%+29.5%1.900% 5/12/2021Geode Capital Management LLC14,180$52K0.0%N/A0.145% 5/7/2021BlackRock Inc.18,277$68K0.0%+35.1%0.187% (Data available from 1/1/2016 forward) PTPI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PTPI shares? During the previous two years, the following institutional investors and hedge funds held shares of Petros Pharmaceuticals shares: Jane Street Group LLC ($39K), Bank of Montreal Can ($27K).Learn more on Petros Pharmaceuticals' institutional investors. What percentage of Petros Pharmaceuticals' stock is owned by institutional investors? 12.34% of Petros Pharmaceuticals' stock is owned by institutional investors. Learn more on PTPI's institutional investor holdings. Which institutional investors have been buying Petros Pharmaceuticals' stock? The following institutional investors have purchased Petros Pharmaceuticals' stock in the last 24 months: Jane Street Group LLC ($563.59K), and Bank of Montreal Can ($10K). How much institutional buying is happening at Petros Pharmaceuticals? Institutional investors have bought a total of 563,594 shares in the last 24 months. This purchase volume represents approximately $973.61K in transactions. Related Companies InMed Pharmaceuticals Institutional Ownership Polyrizon Institutional Ownership Evoke Pharma Institutional Ownership Lipella Pharmaceuticals Institutional Ownership Dermata Therapeutics Institutional Ownership Clearmind Medicine Institutional Ownership Can-Fite BioPharma Institutional Ownership CERo Therapeutics Institutional Ownership Sonnet BioTherapeutics Institutional Ownership Adial Pharmaceuticals Institutional Ownership This page (NASDAQ:PTPI) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
